Navan Announces Confidential Submission of Draft Registration Statement
PALO ALTO, Calif.--(BUSINESS WIRE)--Navan, Inc. has confidentially submitted a draft registration statement on Form S-1 with the SEC relating to a proposed initial public offering. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed initial public offering remains subject to the completion of the SEC review process as well as market and other conditions.
This announcement is being issued pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended ("Securities Act"). This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations of offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.
About Navan
Navan, the leading all-in-one business travel and expense management solution that makes travel easy for frequent travelers. From finding flights and hotels, to automating expense reconciliation, with 24/7 support along the way, Navan delivers an intuitive experience travelers love and finance teams rely on. See how Navan customers benefit and learn more at navan.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
In a Context of Critical Financial Situation, CARMAT Launches a Donation Campaign Open to All to Contribute to Its Funding and Continuation of Its Activities
Risk of insolvency as early as end of June 2025 Launch of a donation campaign open to all via the online platform To listen to CARMAT CEO's message,click here PARIS, June 20, 2025--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announces the launch of a donation campaign open to all, to help fund its operations and continue its mission. Critical financial situation and risk of insolvency at the end of June 2025 In a separate press release published today (see the press release), CARMAT announced that it is currently in a critical financial situation and facing a risk of insolvency as early as the end of June 2025. The Company estimates its 12-month financial needs at approximately €35 million, including €3.5 million needed urgently before the end of June 2025, and an additional €4.5 million by the end of July 2025. Despite efforts that are still ongoing, the Company has not yet been able to secure the financing required to continue its operations. Launch of a donation campaign Against this backdrop, and while continuing its efforts to raise funds, particularly through potential capital increases, CARMAT is today launching a donation campaign open to all. This initiative aims to allow individuals and organizations who support CARMAT's mission and wish to contribute to the continuity of its operations to do so. Practical information on the donation campaign The campaign opens on Friday, June 20, 2025. Donations can only be made via the platform (available on this link). Should they experience issues, donors are invited to contact CARMAT at the following email address: donor@ Main risks associated with donations Potential donors' attention is drawn to the fact that donations made as part of this campaign are non-refundable and do not entail any equity stake in the Company. Donors will therefore not become creditors or shareholders of CARMAT through their donation. Donors should also be aware that there is no guarantee that the donations received as part as this campaign, even in combination with any potential capital increases or other financing solutions that the Company could secure, will be sufficient to prevent a default at the end of June 2025 or beyond. As such, a default of the Company remains possible, even in the very short term. Furthermore, donations made in the context of this campaign do not entitle donors to any tax benefits of any kind. CARMAT, one of the most innovative French medtech companies in the world A technological breakthrough: Aeson®, the world's first physiological artificial heart, to be both pulsatile, self-regulated, and highly hemocompatible Increasing adoption by the medical community: over 120 patients treated worldwide, including more than 70 over the past 18 months Recognition by experts worldwide: more than 60 hospitals trained across 17 countries A team of around 180 highly skilled and committed people Stéphane Piat, Chief Executive Officer of CARMAT, concludes: "After 30 years of research and with 120 patients treated, CARMAT's artificial heart is now the most advanced artificial heart in the world and the most credible solution to address the major challenge of advanced heart failure. This condition is currently the world's leading cause of death. As of today, heart transplantation remains the gold standard treatment, but human donor hearts are unfortunately not available in sufficient numbers, leaving thousands of patients without any solution every year. CARMAT's heart is therefore absolutely essential to fight this growing health crisis and bring hope to patients and their families. In order to continue its mission, CARMAT urgently needs €3.5 million by the end of June 2025, and approximately €35 million over the next 12 months. Failing that, we will most likely be forced to cease operations. Despite our best efforts in a highly deteriorated environment, we have not yet been able to secure the financing required to continue our mission. This is why we are today calling on everyone's generosity to help CARMAT continue saving lives." About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company's ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Name: CARMATISIN code: FR0010907956Ticker: ALCAR Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the "AMF") under number D.25-0345 (the "2024 Universal Registration Document"), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway extends only until the end of June 2025, and that CARMAT is therefore facing a very high risk of default, including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA). View source version on Contacts CARMAT Stéphane Piat Chief Executive Officer Pascale d'Arbonneau Deputy Chief Executive Officer & Chief Financial OfficerTel.: +33 1 39 45 64 50contact@ NewCap Press RelationsNicolas Merigeau Arthur Rouillé Tel.: +33 1 44 71 94 98carmat@ NewCap Financial Communication & Investor RelationsDusan Oresansky Jérémy Digel Tel.: +33 1 44 71 94 92carmat@
Business Wire
37 minutes ago
- Business Wire
DentalMonitoring Launches "Top Ortho Practice Award" to Recognize Data-Driven Excellence in Orthodontic Care
PARIS--(BUSINESS WIRE)--DentalMonitoring, the global leader in AI-powered remote monitoring for orthodontics, is proud to announce the launch of the Top Ortho Practice Award, the first-of-its-kind recognition program that celebrates top-performing orthodontic practices worldwide through objective, data-based analysis. 'The Top Ortho Practice Award is the first global program to recognize orthodontic excellence based on objective clinical data, not popularity.' Unlike traditional awards based on subjective nominations or popularity, the Top Ortho Practice Award is rooted in objective metrics derived from millions of patient scans and clinical interactions. Practices are selected based on exceptional outcomes in hygiene, compliance, and treatment effectiveness, using standardized benchmarks that reflect regional and global performance levels. The program identifies and celebrates practices that lead their territories in performance metrics derived from actual patient data, including hygiene, clinical techniques, and post-treatment stability. These practices will also serve as mentors and knowledge hubs, openly sharing their techniques, workflows, and philosophies to support peer learning and collective growth. DentalMonitoring will host its first Top Ortho Practice Exchange Event live in Las Vegas on September 18th, 2025, before the OP Summit 2025. Sign up here to register 'This initiative is about more than recognition — it's about raising the bar for what's possible in orthodontic care,' said Philippe Salah, CEO of DentalMonitoring. 'By highlighting data-backed excellence, we're helping the industry move toward more measurable, scalable impact.' Through this initiative, DentalMonitoring reaffirms its commitment to transforming orthodontics, motivating practices to unlock their full potential, and ultimately supporting them in delivering better care to patients everywhere. About DentalMonitoring DentalMonitoring sets new standards in orthodontics with its AI-powered, FDA De Novo-approved, and MDR-certified remote monitoring software. Designed for use with multiple appliances or treatment phases, it enables doctors to monitor patients remotely, enhance clinical control, and improve efficiency. Patients benefit from features like in-app messaging, convenient guided scans, and real-time feedback. With its latest innovations, DentalMonitoring helps practices optimize workflows and deliver outstanding care. With over 13,000 clinical data results, DentalMonitoring is transforming the orthodontic experience for patients and practices worldwide by connecting innovation with orthodontic needs.
Yahoo
39 minutes ago
- Yahoo
Southwest Gas completes sale of Centuri Holdings shares
Southwest Gas Holdings has completed its underwritten secondary public offering of Centuri Holdings common stock, with the company acting as the selling stockholder. The offering involved the sale of 11.2 million existing shares at a price of $20.75 per share, generating substantial proceeds for the company. The transaction included the full exercise of the underwriters' option to purchase an additional 1.4 million shares to cover over-allotments. This move underscores the strong market interest and successful execution of the offering strategy. In a concurrent development, Southwest Gas Holdings has also reached an agreement to sell 1,060,240 shares of Centuri's common stock to investment entities affiliated with Carl C. Icahn in a private placement, priced equally to the public offering. This private sale is contingent on regulatory clearances and customary closing conditions, with a termination date set for 9 July 2025 if not finalised. The shares involved in the private placement with the Icahn entities will not be registered under the Securities Act of 1933, indicating a different regulatory approach compared with the public offering. From the public offering, Southwest Gas Holdings has netted approximately $225m after deducting underwriting discounts and commissions. The private placement is expected to bring in an additional $22m. These funds will be allocated towards repaying existing company debts. Following the closing of the public offering, Southwest Gas Holdings' ownership in Centuri stands at approximately 53.3%. The completion of the private placement will slightly reduce this stake to around 52.1%. "Southwest Gas completes sale of Centuri Holdings shares" was originally created and published by Offshore Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
